Subsequent Event - Additional Information (Details) - Oct. 30, 2015 - Subsequent Event - BioNovion Holding B.V.,	EUR (€) shares	USD ($)	EUR (€)
Subsequent Event [Line Items]
Cash paid for business acquisition	€ 14,500,000
Issuance of common stock shares for acquisition of business | shares	697,306
Business acquisition contingent payments, description	The Sellers have the opportunity to receive additional contingent payments from Aduro as follows: (i) EUR 6,000,000 upon acceptance by the U.S. Food and Drug Administration of an investigational new drug application for a specified BioNovion antibody product candidate; and (ii) EUR 20,000,000 upon receipt by BioNovion of a $40,000,000 milestone payment by the licensee under a pre-existing antibody discovery and license agreement, triggered by marketing authorization for the first indication in the United States for a specified BioNovion antibody product candidate.
Business acquisition additional contingent payments			€ 20,000,000
Milestone payments receivable by licensee | $		$ 40,000,000
U.S. Food and Drug Administration
Subsequent Event [Line Items]
Business acquisition additional contingent payments			€ 6,000,000